Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location
Overview
Authors
Affiliations
Background: Radical cholecystectomy is recommended for T2 gallbladder cancer. However, it is unclear whether hepatic resection is essential for peritoneal-side gallbladder cancer.
Methods: From January 2000 to December 2011, we identified T2 gallbladder cancer patients who had undergone curative intent surgery. A peritoneal-side tumor was defined when the epicenter of the tumor was located within the free peritoneal-side gallbladder mucosa. Hepatic-side gallbladder cancer was defined when the epicenter of the tumor was located within the gallbladder bed or neck.
Results: A total of 157 patients with T2 gallbladder cancer were included; 33 peritoneal-side and 124 hepatic-side tumors. In total, 122 patients underwent hepatic resection, whereas the remaining 35 patients did not. After a median follow-up period of 40 (range 5-170) months, the survival of the peritoneal-side group was better than that of the hepatic-side group (p = 0.002). In a multivariate analysis, tumor location, lymph node metastasis, hepatic resection, lymphatic invasion, and perineural invasion were significant prognostic factors (p = 0.045, p < 0.001, p = 0.003, p = 0.046, and p = 0.027, respectively). For the peritoneal-side group, there was no recurrence or death after cholecystectomy without hepatic resection. However, hepatic resection was an important factor associated with overall survival in patients with hepatic-side gallbladder cancer (p = 0.007).
Conclusions: In T2 gallbladder cancer patients, hepatic resection is recommended when there is tumor invasion of the gallbladder bed or neck. However, it is not always necessary in selected patients with peritoneal-side gallbladder cancer.
Li X, Ma T, Li T World J Gastrointest Surg. 2024; 16(10):3239-3252.
PMID: 39575289 PMC: 11577418. DOI: 10.4240/wjgs.v16.i10.3239.
Research progress on prognostic factors of gallbladder carcinoma.
Miao W, Liu F, Guo Y, Zhang R, Wang Y, Xu J J Cancer Res Clin Oncol. 2024; 150(10):447.
PMID: 39369366 PMC: 11456552. DOI: 10.1007/s00432-024-05975-0.
Piccolo G, Barabino M, Piozzi G, Bianchi P World J Gastroenterol. 2024; 30(32):3739-3742.
PMID: 39221070 PMC: 11362876. DOI: 10.3748/wjg.v30.i32.3739.
Guner M, Kaya T Cureus. 2023; 15(10):e47249.
PMID: 37859674 PMC: 10583125. DOI: 10.7759/cureus.47249.
Chen Z, Yu J, Cao J, Lin C, Hu J, Zhang B Front Oncol. 2023; 13:1186378.
PMID: 37469411 PMC: 10352769. DOI: 10.3389/fonc.2023.1186378.